<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368316</url>
  </required_header>
  <id_info>
    <org_study_id>999900003</org_study_id>
    <secondary_id>OH00-CH-N003</secondary_id>
    <nct_id>NCT00368316</nct_id>
  </id_info>
  <brief_title>Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel</brief_title>
  <official_title>Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Chaim Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schneider Children's Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shigellosis remains a serious and frequent disease throughout the world. Development of
      vaccines has been difficult because shigellae are habitants of and pathogens for humans only
      and there is no consensus about the mechanism(s) of immunity to this pathogen.

      Incomplete, but compelling evidence, indicates that a critical level of serum IgG anti-LPS
      confers immunity to shigellosis. Important data come from our clinical trial in the Israel
      Defense Forces (IDF) recruits. A randomized, double-blind, vaccine-controlled study showed
      that the S. sonnei-rEPA elicited 74% protection against shigellosis occurring about 3 months
      after vaccination (p=0.001). This vaccine conferred 43% (p=0.04) protection in one company
      during an outbreak up to 14 days following vaccination suggesting that our Shigella
      conjugates might be of value in epidemics. The efficacy of S. sonnei-rEPA was correlated with
      the level of vaccine-induced IgG antibodies.

      The highest incidence, morbidity, and mortality of shigellosis is in young children. But
      serum antibody responsiveness to polysaccharide-based vaccines is age-dependent and infants
      and young children respond poorly or not at all to both disease and vaccination. The safety
      and immunogenicity of these Shigella conjugates in 4 to 6 years-old children in Israel was
      demonstrated. But although the fold rise in anti-LPS was similar in the children, the level
      of anti-LPS elicited by the conjugates was lower than in adults. We improved the
      immunogenicity of Shigella conjugates as shown in mice and then in adult humans. Now we apply
      to evaluate the safety, immunogenicity and efficacy of these improved conjugates in 1 to 4
      years-old children in Israel.

      In Israel, shigellosis is common especially in children. S. sonnei (Group D) comprise about
      60% of the isolates followed by S. flexneri (Group B): Shigella dysenteriae type 1 (Group A)
      is not found. We propose to administer 2 injections of either S. sonnei-CRM9 or S. flexneri
      type 2a-rEPAsucc 6 weeks apart in a random double-blind fashion to about 6,000 1 to 4
      year-olds. Active surveillance of the vaccinees for enteric infections will be maintained for
      at least 2 years to evaluate the effect of vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Shigellosis remains a serious and frequent disease throughout the world. Development of
      vaccines has been difficult because shigellae are habitants of and pathogens for humans only
      and there is no consensus about the mechanism/s of immunity to this pathogen.

      Incomplete, but compelling evidence, indicates that a critical level of serum IgG anti-LPS
      confers immunity to shigellosis. A randomized, double-blind, vaccine-controlled study in
      Israel Defense Force (IDF) recruits showed that the S. sonnei-rEPA elicited 74% protection
      against shigellosis occurring about 3 months after vaccination (p=0.001). This vaccine also
      conferred 43% (p=0.04) protection in one company during an outbreak up to 17 days following
      vaccination suggesting that our Shigella conjugates might be of value in epidemics. The
      efficacy of S. sonnei-rEPA was correlated with the level of vaccine-induced IgG antibodies.

      The highest incidence, morbidity, and mortality of shigellosis is in young children. But
      serum antibody responsiveness to it is age dependent and infants and young children respond
      poorly or not at all to polysaccharide antigens following disease, administration of
      attenuated strains of Shigella or vaccination with whole cell vaccines. The safety and
      immunogenicity of similar Shigella conjugates in 4 to 7 years-old children in Israel was
      demonstrated. But, although the fold rise in anti-LPS was similar in the children, the level
      of anti-LPS elicited by the conjugates was lower than in adults. We improved the
      immunogenicity of Shigella conjugates as shown in mice and then in adult humans. Now we apply
      to evaluate the safety, immunogenicity and efficacy of these improved conjugates in 1 to 4
      years-old children in Israel. In addition to monitoring the safety and immunogenicity of the
      two investigational Shigella vaccines, active surveillance of the vaccines for enteric
      infections wil be maintained for at lest 2 years to evaluate the effect of vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Monitored for 7 days per participant following each injection for initial group of 500, 2 days for extended study of up to 5500 additional children</time_frame>
    <description>Number of participants with events per vaccine type and dose occuring in &gt;=5% of participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Immunoglobulin G (IgG) Anti-Lipopolysaccharide (LPS) Levels</measure>
    <time_frame>Injections were administered 6 weeks apart and IgG anti-LPS levels determined &gt;2 weeks after second vaccine dose. Each of the 15 sites also took a sample/week randomly chosen, for 2 years of follow up and blood samples from patients with disease</time_frame>
    <description>Age-related homologous IgG anti-LPS levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Efficacy</measure>
    <time_frame>During 2 years post vaccination</time_frame>
    <description>Percent efficacy is defined as ((disease rate of controls minus disease rate of vaccinees) divided by disease rate of controls) times 100</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2799</enrollment>
  <condition>Shigellosis</condition>
  <arm_group>
    <arm_group_label>S. sonnei conjugate vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S. flexneri 2a conjugate vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of pseudomonas aeruginosa</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Shigella conjugate vaccines</intervention_name>
    <description>Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines</description>
    <arm_group_label>S. sonnei conjugate vaccine</arm_group_label>
    <arm_group_label>S. flexneri 2a conjugate vaccine</arm_group_label>
    <other_name>S. sonnei O-SP-rEPA conjugate.</other_name>
    <other_name>S. flexneri 2a O-SP-rEPA conjugate.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Volunteers who are healthy 1-4 year old children whose parents/guardians have read the
        Information Sheet provided by the Principal Investigator and signed the consent form, and
        who will be available for follow up.

        EXCLUSION CRITERIA: Children with

          -  chronic diseases receiving medication;

          -  who have received systemic steroids during the month preceding Shigella vaccination;

          -  who had severe side effects following vaccinations; and

          -  those not available for follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Schneerson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PDMI, NICHD, NIH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schneider Childrens Hospital</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Development of vaccines against shigellosis: memorandum from a WHO meeting. Bull World Health Organ. 1987;65(1):17-25.</citation>
    <PMID>3495364</PMID>
  </reference>
  <reference>
    <citation>DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis. 1972 Jan;125(1):12-6.</citation>
    <PMID>4550416</PMID>
  </reference>
  <reference>
    <citation>Taylor DN, Echeverria P, Blaser MJ, Pitarangsi C, Blacklow N, Cross J, Weniger BG. Polymicrobial aetiology of travellers' diarrhoea. Lancet. 1985 Feb 16;1(8425):381-3.</citation>
    <PMID>2857430</PMID>
  </reference>
  <reference>
    <citation>Hossain MA, Hasan KZ, Albert MJ. Shigella carriers among non-diarrhoeal children in an endemic area of shigellosis in Bangladesh. Trop Geogr Med. 1994;46(1):40-2.</citation>
    <PMID>8165738</PMID>
  </reference>
  <reference>
    <citation>Huilan S, Zhen LG, Mathan MM, Mathew MM, Olarte J, Espejo R, Khin Maung U, Ghafoor MA, Khan MA, Sami Z, et al. Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. Bull World Health Organ. 1991;69(5):549-55.</citation>
    <PMID>1659953</PMID>
  </reference>
  <reference>
    <citation>Struelens MJ, Patte D, Kabir I, Salam A, Nath SK, Butler T. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis. 1985 Oct;152(4):784-90.</citation>
    <PMID>4045231</PMID>
  </reference>
  <results_reference>
    <citation>Passwell JH, Ashkenzi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R; Israeli Shigella Study Group. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine. 2010 Mar 2;28(10):2231-5. doi: 10.1016/j.vaccine.2009.12.050. Epub 2010 Jan 5.</citation>
    <PMID>20056180</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2006</study_first_submitted>
  <study_first_submitted_qc>August 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2006</study_first_posted>
  <results_first_submitted>May 9, 2012</results_first_submitted>
  <results_first_submitted_qc>May 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2012</results_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysentery</keyword>
  <keyword>S. sonnei</keyword>
  <keyword>Antibody Response</keyword>
  <keyword>Protection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment period: May 1, 2003 to January 31 3006. Surveillance period: May 1, 2003 to January 31 2008. Children were recruited from day care centers and health clinics in Israel</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>S. Sonnei Conjugate Vaccine</title>
          <description>Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
        </group>
        <group group_id="P2">
          <title>S. Flexneri 2a Conjugate Vaccine</title>
          <description>Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1434"/>
                <participants group_id="P2" count="1365"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1392"/>
                <participants group_id="P2" count="1319"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>S. Sonnei Conjugate Vaccine</title>
          <description>Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
        </group>
        <group group_id="B2">
          <title>S. Flexneri 2a Conjugate Vaccine</title>
          <description>Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1434"/>
            <count group_id="B2" value="1365"/>
            <count group_id="B3" value="2799"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1434"/>
                    <measurement group_id="B2" value="1365"/>
                    <measurement group_id="B3" value="2799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="702"/>
                    <measurement group_id="B2" value="642"/>
                    <measurement group_id="B3" value="1344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="732"/>
                    <measurement group_id="B2" value="723"/>
                    <measurement group_id="B3" value="1455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1434"/>
                    <measurement group_id="B2" value="1365"/>
                    <measurement group_id="B3" value="2799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of participants with events per vaccine type and dose occuring in &gt;=5% of participants</description>
        <time_frame>Monitored for 7 days per participant following each injection for initial group of 500, 2 days for extended study of up to 5500 additional children</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S. Sonnei Conjugate Vaccine</title>
            <description>Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
          </group>
          <group group_id="O2">
            <title>S. Flexneri 2a Conjugate Vaccine</title>
            <description>Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of participants with events per vaccine type and dose occuring in &gt;=5% of participants</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1434"/>
                <count group_id="O2" value="1365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>local pain, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>local pain, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fever, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fever, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Immunoglobulin G (IgG) Anti-Lipopolysaccharide (LPS) Levels</title>
        <description>Age-related homologous IgG anti-LPS levels</description>
        <time_frame>Injections were administered 6 weeks apart and IgG anti-LPS levels determined &gt;2 weeks after second vaccine dose. Each of the 15 sites also took a sample/week randomly chosen, for 2 years of follow up and blood samples from patients with disease</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S. Sonnei Conjugate Vaccine</title>
            <description>Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
          </group>
          <group group_id="O2">
            <title>S. Flexneri 2a Conjugate Vaccine</title>
            <description>Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Immunoglobulin G (IgG) Anti-Lipopolysaccharide (LPS) Levels</title>
          <description>Age-related homologous IgG anti-LPS levels</description>
          <units>ELISA units</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1434"/>
                <count group_id="O2" value="1365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age 1-2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40">No measure of dispersion was calculated. The medically responsible investigator in Israel died.</measurement>
                    <measurement group_id="O2" value="18.98">No measure of dispersion was calculated. The medically responsible investigator in Israel died.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age &gt;2-3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71">No measure of dispersion was calculated. The medically responsible investigator in Israel died.</measurement>
                    <measurement group_id="O2" value="26.96">No measure of dispersion was calculated. The medically responsible investigator in Israel died.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age &gt;3-4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38">No measure of dispersion was calculated. The medically responsible investigator in Israel died.</measurement>
                    <measurement group_id="O2" value="43.86">No measure of dispersion was calculated. The medically responsible investigator in Israel died.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Efficacy</title>
        <description>Percent efficacy is defined as ((disease rate of controls minus disease rate of vaccinees) divided by disease rate of controls) times 100</description>
        <time_frame>During 2 years post vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S. Sonnei Conjugate Vaccine</title>
            <description>Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
          </group>
          <group group_id="O2">
            <title>S. Flexneri 2a Conjugate Vaccine</title>
            <description>Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Efficacy</title>
          <description>Percent efficacy is defined as ((disease rate of controls minus disease rate of vaccinees) divided by disease rate of controls) times 100</description>
          <units>Percent efficacy</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1434"/>
                <count group_id="O2" value="1365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants aged 1-2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="-101.1" upper_limit="46.5"/>
                    <measurement group_id="O2" value="-8.4" lower_limit="-434.5" upper_limit="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants aged &gt;2-3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="-56.4" upper_limit="73.4"/>
                    <measurement group_id="O2" value="22.5" lower_limit="-244.4" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants aged &gt;3-4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" lower_limit="-4.43" upper_limit="92.0"/>
                    <measurement group_id="O2" value="-3.6" lower_limit="-1550" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Local and systemic reactions were sought at 30 minutes, 6, 24 and 48 hours after vaccination by a structured questionnaire.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>S. Sonnei Conjugate Vaccine</title>
          <description>Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
        </group>
        <group group_id="E2">
          <title>S. Flexneri 2a Conjugate Vaccine</title>
          <description>Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, administered in 2 injections of 0.5 mL containing 25 mcg of saccharide, 6 weeks apart</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1434"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1365"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="1434"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="1365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever, dose 2</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="1434"/>
                <counts group_id="E2" events="72" subjects_affected="72" subjects_at_risk="1365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>fever, dose 1</sub_title>
                <counts group_id="E1" events="56" subjects_affected="56" subjects_at_risk="1434"/>
                <counts group_id="E2" events="72" subjects_affected="72" subjects_at_risk="1365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>local pain, dose 1</sub_title>
                <counts group_id="E1" events="82" subjects_affected="82" subjects_at_risk="1434"/>
                <counts group_id="E2" events="61" subjects_affected="61" subjects_at_risk="1365"/>
              </event>
              <event>
                <sub_title>local pain, dose 2</sub_title>
                <counts group_id="E1" events="79" subjects_affected="79" subjects_at_risk="1434"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="1365"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No efficacy could be assessed after 2nd injection of S. sonnei conjugate due to the small number of positive isolates at that time. There were too few cases of S. flexneri 2a infection for evaluation of vaccine B efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Rachel Schneerson, Co-Director</name_or_title>
      <organization>PDMI, NICHD, NIH</organization>
      <phone>301-469-0850</phone>
      <email>schneerr@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

